In the second and final part of her interview with The American Journal of Managed Care ® (AJMC ®), Cherie Daly, MD, director ...
Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...
INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting ...
Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers. Spira: There are a couple of reasons why. First of ...
Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...
Learn how tumor and liquid biopsy biomarker tests are ordered, why results take weeks, and how insurance rules can delay cancer treatment. In ‘Unmet Needs and Emerging Mechanisms of Action in ...
In the final episode, 'Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care,' the panelists ...
Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer ...
Survivorship care and patient follow-up, being pivotal to managing treatment plans for patients with breast cancer, were key ...
Objectives: The burden of a new cancer diagnosis on state Medicaid programs is not well understood. Our study aimed to (1) ...
Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...
As prescription drug affordability boards move toward upper payment limit implementation, uncertainties introduced across the health care system and risks to patient access warrant urgent attention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results